- Home
- ACXP vs UNCY Comparison
ACXP vs UNCY Comparison
Compare ACXP & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- UNCY
- Stock Information
- Founded
- ACXP 2017
- UNCY 2016
- Country
- ACXP United States
- UNCY United States
- Employees
- ACXP N/A
- UNCY N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- UNCY Health Care
- Exchange
- ACXP Nasdaq
- UNCY Nasdaq
- Market Cap
- ACXP 31.4M
- UNCY 31.9M
- IPO Year
- ACXP 2021
- UNCY 2021
- Fundamental
- Price
- ACXP $0.87
- UNCY $0.70
- Analyst Decision
- ACXP Strong Buy
- UNCY Strong Buy
- Analyst Count
- ACXP 1
- UNCY 4
- Target Price
- ACXP $12.00
- UNCY $5.50
- AVG Volume (30 Days)
- ACXP 297.3K
- UNCY 1.4M
- Earning Date
- ACXP 11-12-2024
- UNCY 11-13-2024
- Dividend Yield
- ACXP N/A
- UNCY N/A
- EPS Growth
- ACXP N/A
- UNCY N/A
- EPS
- ACXP N/A
- UNCY N/A
- Revenue
- ACXP N/A
- UNCY N/A
- Revenue This Year
- ACXP N/A
- UNCY N/A
- Revenue Next Year
- ACXP N/A
- UNCY N/A
- P/E Ratio
- ACXP N/A
- UNCY N/A
- Revenue Growth
- ACXP N/A
- UNCY N/A
- 52 Week Low
- ACXP $0.72
- UNCY $0.20
- 52 Week High
- ACXP $5.28
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- ACXP 31.17
- UNCY 55.55
- Support Level
- ACXP $0.84
- UNCY $0.62
- Resistance Level
- ACXP $0.91
- UNCY $0.87
- Average True Range (ATR)
- ACXP 0.12
- UNCY 0.07
- MACD
- ACXP 0.02
- UNCY -0.01
- Stochastic Oscillator
- ACXP 28.07
- UNCY 25.00
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.